{"id":"W4206915368","doi":"10.1093/ecco-jcc/jjab232.035","title":"OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study","year":2022,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Ulcerative colitis; Internal medicine; Clinical endpoint; Golimumab; Gastroenterology; Combination therapy; Surgery; Randomized controlled trial; Tumor necrosis factor alpha; Infliximab; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006558095,0.000215126,0.0008179434,0.0001191534,0.0001239344,0.00002757686,0.00009390691,0.00006412392,0.000005780415],"category_scores_gemma":[0.00007415519,0.000162477,0.00006881576,0.0001136012,0.0002738191,0.00007027484,0.00006445168,0.0001892713,1.679522e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004709288,"about_ca_system_score_gemma":0.0002197687,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001147672,"about_ca_topic_score_gemma":0.0002759885,"domain_scores_codex":[0.9976679,0.0006719328,0.0008361769,0.0002823291,0.000326782,0.0002148689],"domain_scores_gemma":[0.9981819,0.0001096237,0.001027268,0.0001440399,0.0004220207,0.0001151408],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9804801,0.003366381,0.0001378528,0.00003449972,0.0008951781,0.00007485636,0.0107676,0.001054671,0.0002587708,0.00009433668,0.000004786716,0.002831006],"study_design_scores_gemma":[0.7604613,0.0110305,0.212036,0.0001185727,0.0002325914,0.00005133464,0.006803665,0.0002540075,0.00872241,0.00008306908,0.00002161855,0.0001849526],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956299,0.0002880142,0.0003298098,0.00007268861,0.00003673843,0.003439846,0.0001443918,0.000001876594,0.00005670741],"genre_scores_gemma":[0.9992712,0.0001894735,0.0001843296,0.0000278018,0.00002797847,0.0002418164,0.000022177,0.00001829419,0.00001691071],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2200188,"threshold_uncertainty_score":0.662562,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02813589145306264,"score_gpt":0.2998586161774069,"score_spread":0.2717227247243442,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}